DIFFERENT RATE OF DESENSITIZATION IN THE MULTIPLE SIGNALING PATHWAYS OF OPIOID RECEPTOR

RNA-injected Xenopus oocytes were used for studying homologous desensitization of opioid receptors to G-protein-coupled intracellular signaling pathways. In the oocytes expressing K opioid receptor, voltage-dependent Ca2+ channel α2+ and β subunits, the κ agonist U50488H (1 μM) inhibited Ca2+ channe...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Folia Pharmacologica Japonica 1995, Vol.106(supplement), pp.147-151
Hauptverfasser: Kaneko, Shuji, Yada, Nobumichi, Adachi, Kei, Akaike, Akinori, Satoh, Masamichi
Format: Artikel
Sprache:eng ; jpn
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:RNA-injected Xenopus oocytes were used for studying homologous desensitization of opioid receptors to G-protein-coupled intracellular signaling pathways. In the oocytes expressing K opioid receptor, voltage-dependent Ca2+ channel α2+ and β subunits, the κ agonist U50488H (1 μM) inhibited Ca2+ channel current in a reversible manner, and the inhibition was diminished by sustained agonist exposure (homologous desensitization). More than 10 min was required to halve the inhibition of BI- or Q-type Ca2+ channels by the κ agonist, however, the t½ for U50488H-induced inhibition of BIII- or N-type channels was only 6±1 min. Moreover, in the oocytes expressing κ opioid receptor, EP4 prostaglandin receptor and CFTR channel, no apparent desensitization was observed in the κ receptor-mediated potentiation of the cyclic AMP production by prostaglandin E2 even when the oocytes were treated with U50488H for 2 hours or more. The time-course of desensitization of μ opioid receptor was also different in the effector molecules. These observations suggest that rate of homologous desensitization of opioid receptor is not only dependent on the receptor molecule itself but also on its intracellular signaling systems.
ISSN:0015-5691
1347-8397
DOI:10.1254/fpj.106.supplement_147